Zelboraf

Active ingredient
Vemurafenib
Pharma Company
Roche Pharma AG/ Roche Deutschland Holding GmbH
Total Number of Doctors1
32 doctors
Total Number of Patients2
300 patients
Total minimum fees planned3
687,000.00 €

Observational Studies including Zelboraf

Drug No. of doctors1 No. of patients2 Payment per patient3
Zelboraf 32 300 2,290.00 € Baselinevisite: 458,00, 8 Visiten à 229,00, plus einmalig 500,00 für Studie

Background

Independent journalism needs independent funding

Others can write stories. We want to reveal. We are the first investigative newsroom in Germany, which is independent, ad-free, and non-profit.

For us, the core of journalism means uncovering injustice and shortcomings in society. That’s why we investigate corruption in the health system, politicians abusing their power, and an elite that believes that rules are for the others.

To do our job, we need people, who support us. We ask you, too, to become a member and enable the work of 16 investigative journalists at CORRECTIV.

We are convinced that without independent and critical media, democracy fought for and won by our ancestors, cannot survive for long.